Literature DB >> 34580702

Circulating Ceramides and Sphingomyelins and Risk of Mortality: The Cardiovascular Health Study.

Amanda M Fretts1, Paul N Jensen2, Andrew N Hoofnagle3, Barbara McKnight4, Colleen M Sitlani2, David S Siscovick5, Irena B King6, Bruce M Psaty7, Nona Sotoodehnia2, Rozenn N Lemaitre2.   

Abstract

BACKGROUND: Recent studies suggest that associations of ceramides (Cer) and sphingomyelins (SM) with health outcomes differ according to the fatty acid acylated to the sphingoid backbone. The purpose of this study was to assess associations of Cer and SM species with mortality.
METHODS: The study population included participants from the Cardiovascular Health Study (CHS), a community-based cohort of adults aged ≥65 years who were followed from 1992-2015 (n = 4612). Associations of plasma Cer and SM species carrying long-chain (i.e., 16:0) and very-long-chain (i.e., 20:0, 22:0, 24:0) saturated fatty acids with mortality were assessed using Cox proportional hazards models.
RESULTS: During a median follow-up of 10.2 years, 4099 deaths occurred. High concentrations of Cer and SM carrying fatty acid 16:0 were each associated with an increased risk of mortality. Conversely, high concentrations of several ceramide and sphingomyelin species carrying longer fatty acids were each associated with a decreased risk of mortality. The hazard ratios for total mortality per 2-fold difference in each Cer and SM species were: 1.89 (95% CI), 1.65-2.17 for Cer-16, 0.79 (95% CI, 0.70-0.88) for Cer-22, 0.74 (95% CI, 0.65-0.84) for Cer-24, 2.51 (95% CI, 2.01-3.14) for SM-16, 0.68 (95% CI, 0.58-0.79) for SM-20, 0.57 (95% CI, 0.49-0.67) for SM-22, and 0.66 (0.57-0.75) for SM-24. We found no association of Cer-20 with risk of death.
CONCLUSIONS: Associations of Cer and SM with the risk of death differ according to the length of their acylated saturated fatty acid. Future studies are needed to explore mechanisms underlying these relationships. © American Association for Clinical Chemistry 2021. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34580702      PMCID: PMC8634404          DOI: 10.1093/clinchem/hvab182

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  45 in total

1.  The Cardiovascular Health Study: design and rationale.

Authors:  L P Fried; N O Borhani; P Enright; C D Furberg; J M Gardin; R A Kronmal; L H Kuller; T A Manolio; M B Mittelmark; A Newman
Journal:  Ann Epidemiol       Date:  1991-02       Impact factor: 3.797

2.  Plasma Ceramides and Sphingomyelins in Relation to Heart Failure Risk.

Authors:  Rozenn N Lemaitre; Paul N Jensen; Andrew Hoofnagle; Barbara McKnight; Amanda M Fretts; Irena B King; David S Siscovick; Bruce M Psaty; Susan R Heckbert; Dariush Mozaffarian; Nona Sotoodehnia
Journal:  Circ Heart Fail       Date:  2019-07-12       Impact factor: 8.790

3.  Human fatty acid synthesis is stimulated by a eucaloric low fat, high carbohydrate diet.

Authors:  L C Hudgins; M Hellerstein; C Seidman; R Neese; J Diakun; J Hirsch
Journal:  J Clin Invest       Date:  1996-05-01       Impact factor: 14.808

4.  Laboratory methods and quality assurance in the Cardiovascular Health Study.

Authors:  M Cushman; E S Cornell; P R Howard; E G Bovill; R P Tracy
Journal:  Clin Chem       Date:  1995-02       Impact factor: 8.327

Review 5.  Membrane lipids: where they are and how they behave.

Authors:  Gerrit van Meer; Dennis R Voelker; Gerald W Feigenson
Journal:  Nat Rev Mol Cell Biol       Date:  2008-02       Impact factor: 94.444

6.  Ceramide inhibits pancreatic beta-cell insulin production and mitogenesis and mimics the actions of interleukin-1 beta.

Authors:  A Sjöholm
Journal:  FEBS Lett       Date:  1995-07-03       Impact factor: 4.124

7.  Influence of stearic acid on hemostatic risk factors in humans.

Authors:  Tine Tholstrup
Journal:  Lipids       Date:  2005-12       Impact factor: 1.880

8.  Effects of step-wise increases in dietary carbohydrate on circulating saturated Fatty acids and palmitoleic Acid in adults with metabolic syndrome.

Authors:  Brittanie M Volk; Laura J Kunces; Daniel J Freidenreich; Brian R Kupchak; Catherine Saenz; Juan C Artistizabal; Maria Luz Fernandez; Richard S Bruno; Carl M Maresh; William J Kraemer; Stephen D Phinney; Jeff S Volek
Journal:  PLoS One       Date:  2014-11-21       Impact factor: 3.240

9.  Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome.

Authors:  Baris Gencer; David A Morrow; Eugene Braunwald; Erica L Goodrich; Mika Hilvo; Dimple Kauhanen; Marc S Sabatine; Reijo Laaksonen; Michelle L O'Donoghue
Journal:  Eur J Prev Cardiol       Date:  2022-05-06       Impact factor: 7.804

10.  Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency.

Authors:  Kirill Tarasov; Kim Ekroos; Matti Suoniemi; Dimple Kauhanen; Tuulia Sylvänne; Reini Hurme; Ioanna Gouni-Berthold; Heiner K Berthold; Marcus E Kleber; Reijo Laaksonen; Winfried März
Journal:  J Clin Endocrinol Metab       Date:  2013-12-20       Impact factor: 5.958

View more
  3 in total

1.  Plasma ceramides independently predict all-cause mortality in men aged 85.

Authors:  Timo E Strandberg; Mika Kivimäki; Annele Urtamo; Satu Jyväkorpi; Reijo Laaksonen
Journal:  Age Ageing       Date:  2022-06-01       Impact factor: 12.782

Review 2.  Very long-chain saturated fatty acids and diabetes and cardiovascular disease.

Authors:  Rozenn N Lemaitre; Irena B King
Journal:  Curr Opin Lipidol       Date:  2022-02-01       Impact factor: 4.616

Review 3.  Ceramides as Mediators of Oxidative Stress and Inflammation in Cardiometabolic Disease.

Authors:  Melania Gaggini; Rudina Ndreu; Elena Michelucci; Silvia Rocchiccioli; Cristina Vassalle
Journal:  Int J Mol Sci       Date:  2022-02-28       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.